Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Total Non-current Liabilities
All obligations due after more than one year.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Total Non-current Liabilities · Q4 FY2025 · quarter ended Dec 2025
Total non-current liabilities remains negative
Q4 FY2025 total non-current liabilities was $0, compared with $0 a year earlier.
Context
- Total non-current liabilities amounted to 0.0% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Total non-current liabilities amounts to 0.0% of total assets for NNNN, versus a peer median of 11.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $11.58B USD | -9.9% | -3.6% | 87.8% | |
| Dec 2025 | $280.73M USD | — | — | 83.7% | |
| Mar 2026 | $233.88M USD | -2.0% | +3.1% | 181.4% | |
| Mar 2026 | CA$140.21M CAD | +16.0% | +0.1% | 10.7% | |
| Mar 2026 | $136.8M USD | +4.3% | -24.7% | 13.0% | |
| Mar 2026 | $65.1M USD | +1923.5% | +70.9% | 69.7% | |
| Mar 2026 | $51.26M USD | -45.3% | +232.8% | 9.6% | |
| Feb 2026 | $21.26M USD | -1.5% | -27.0% | 8.2% | |
| Mar 2026 | $15.22M USD | -83.2% | -34.8% | 3.0% | |
| Mar 2026 | $325K USD | -81.0% | -31.4% | 0.2% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 USD | — | — | 0.0% |
| Peer median (excluding NNNN) | — | -2.0% | -3.6% | 11.8% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.